Key Points
- Insider sale: Mike Kelliher sold 5,560 Ardelyx shares on November 21 at an average price of $5.54 for $30,802.40, reducing his stake by 2.01% to 271,181 shares (≈$1.50M); the transaction was filed with the SEC.
- Quarterly results: Ardelyx reported $0.00 EPS (vs. -$0.06 est.) and revenue of $110.33M (beat $100.44M), with revenue up 14.6% YoY, though the company still shows a negative net margin and return on equity.
- Market and sentiment: ARDX trades around $5.70 with a $1.39B market cap, institutional ownership of ~58.9%, and an average analyst rating of "Moderate Buy" with a mean price target of about $11.73.
Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Mike Kelliher sold 5,560 shares of the company's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $5.54, for a total transaction of $30,802.40. Following the completion of the transaction, the insider owned 271,181 shares in the company, valued at approximately $1,502,342.74. This trade represents a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ardelyx Trading Up 4.0%
Shares of Ardelyx stock opened at $5.72 on Wednesday. The company has a debt-to-equity ratio of 1.44, a current ratio of 4.30 and a quick ratio of 4.03. Ardelyx, Inc. has a 1 year low of $3.21 and a 1 year high of $6.78. The firm has a market cap of $1.39 billion, a PE ratio of -24.87 and a beta of 0.66. The company has a 50 day simple moving average of $5.52 and a two-hundred day simple moving average of $4.99.
Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $0.00 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.06. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The firm had revenue of $110.33 million for the quarter, compared to analyst estimates of $100.44 million. The company's revenue was up 14.6% compared to the same quarter last year. Analysts expect that Ardelyx, Inc. will post -0.18 earnings per share for the current fiscal year.
Institutional Trading of Ardelyx
Institutional investors have recently made changes to their positions in the stock. DCF Advisers LLC bought a new position in shares of Ardelyx in the second quarter worth approximately $39,000. Brighton Jones LLC bought a new stake in Ardelyx during the 2nd quarter valued at $40,000. Focus Partners Advisor Solutions LLC purchased a new stake in Ardelyx during the 1st quarter valued at $56,000. SBI Securities Co. Ltd. grew its holdings in Ardelyx by 147.0% in the 3rd quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 6,102 shares during the last quarter. Finally, State of Wyoming purchased a new position in shares of Ardelyx in the second quarter valued at about $61,000. Hedge funds and other institutional investors own 58.92% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on ARDX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Ardelyx in a report on Wednesday, October 8th. TD Cowen upped their target price on Ardelyx from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, October 31st. UBS Group set a $12.00 price target on shares of Ardelyx in a research report on Tuesday, August 5th. Citigroup boosted their price objective on shares of Ardelyx from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Monday, November 3rd. Finally, Cowen reaffirmed a "buy" rating on shares of Ardelyx in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Ardelyx has an average rating of "Moderate Buy" and an average price target of $11.73.
Read Our Latest Research Report on Ardelyx
About Ardelyx
(
Get Free Report)
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
